The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
- DOI
- 10.1038/s41591-022-01703-8
- Published
- 2022 Apr
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-022-01703-8,
title = {The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.},
author = {Spertus JA and Birmingham MC and Nassif M and Damaraju CV and Abbate A and Butler J and Lanfear DE and Lingvay I and Kosiborod MN and Januzzi JL},
year = {2022},
journal = {Nature medicine},
doi = {10.1038/s41591-022-01703-8},
url = {https://doi.org/10.1038/s41591-022-01703-8}
}RIS
TY - JOUR TI - The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. AU - Spertus JA AU - Birmingham MC AU - Nassif M AU - Damaraju CV AU - Abbate A AU - Butler J AU - Lanfear DE AU - Lingvay I AU - Kosiborod MN AU - Januzzi JL PY - 2022 JO - Nature medicine DO - 10.1038/s41591-022-01703-8 UR - https://doi.org/10.1038/s41591-022-01703-8 ER -
APA
JA, S., MC, B., M, N., CV, D., A, A., J, B., DE, L., I, L., MN, K., & JL, J. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.. Nature medicine. https://doi.org/10.1038/s41591-022-01703-8
Source records
- pubmed · retrieved 2026-09-26T17:14:22.548Z